Artrya reports lapse of 10,000 performance rights

Artrya Limited ( (AU:AYA) ) has shared an announcement.

Artrya Limited has reported the lapse of 10,000 performance rights, designated under the ASX code AYAAAF, after the conditions attached to those rights were not met or became incapable of being satisfied. The cessation, effective 9 March 2026, represents a minor adjustment to the company’s issued capital base and indicates that specific performance or service milestones tied to these incentives were not achieved, slightly reducing potential future equity dilution for existing shareholders.

The notification underscores Artrya’s ongoing management of its incentive structures and capital position under ASX requirements. While the number of lapsed rights is small relative to typical listed-company capital structures, the move clarifies the status of previously granted conditional securities and provides investors with updated transparency on potential future share issuance tied to performance rights.

The most recent analyst rating on (AU:AYA) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.

More about Artrya Limited

Artrya Limited is an Australian-listed medical technology company focused on developing advanced diagnostic and imaging solutions for cardiovascular disease. The company trades on the ASX under the code AYA and manages a range of equity and performance-based securities as part of its capital structure and employee or executive incentive arrangements.

Average Trading Volume: 589,173

Technical Sentiment Signal: Buy

Current Market Cap: A$537.5M

For a thorough assessment of AYA stock, go to TipRanks’ Stock Analysis page.